Aster Capital Management (Difc) LTD Amylyx Pharmaceuticals, Inc. Call Options Transaction History
Aster Capital Management (Difc) LTD
- $198 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AMLX
# of Institutions
166Shares Held
85.1MCall Options Held
346KPut Options Held
128K-
Perceptive Advisors LLC New York, NY8.95MShares$114 Million0.27% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.82MShares$86.5 Million0.16% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.94MShares$75.4 Million7.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.27MShares$66.9 Million0.0% of portfolio
-
Saturn V Capital Management LLC Austin, TX4.6MShares$58.4 Million13.72% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $743M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...